RenovoRx, Inc. (RNXT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. RenovoRx, Inc. is a commercial and clinical-stage life sciences company focused on the RenovoCath device, an FDA-cleared local drug delivery system. The company is commercializing RenovoCath as a standalone device for interventional oncology while advancing its lead drug-device combination candidate, IAG (intra-arterial gemcitabine), in a pivotal Phase III trial (TIGeR-PaC) for locally advanced pancreatic cancer.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $266,000 | $0 | $885,000 | $0 |
| Gross Profit | $213,000 | $0 | $586,000 | $0 |
| Gross Margin | 80% | N/A | 66% | N/A |
| Net Loss | $(2,912,000) | $(2,471,000) | $(8,227,000) | $(5,936,000) |
| Operating Expenses | $3,413,000 | $2,828,000 | $9,574,000 | $8,338,000 |
| Cash & Equivalents (End of Period) | $10,044,000 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(58,446,000) (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Generation: The company recognized revenue for the first time in Q3 2024 and continued in Q3 2025 ($266k), driven by standalone sales of the RenovoCath device. This contrasts with zero revenue in the prior year periods.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses increased by 47% quarter-over-quarter ($1.73M vs $1.18M) due to professional fees for ERP implementation, remediation of material weaknesses, and increased investor relations costs. R&D expenses remained relatively flat ($1.69M vs $1.65M).
- Financing Activity: In February 2025, the company completed an underwritten public offering raising approximately $10.8 million in net proceeds, significantly bolstering cash reserves compared to the prior year.
- Warrant Liability: The company recorded a gain of $175,000 in Q3 2025 from the change in fair value of common warrant liabilities, compared to $233,000 in Q3 2024.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management explicitly states that current cash ($10.0M) is not sufficient to fund operations for the next 12 months. The company expects to require additional funding to continue operations, commercialize RenovoCath, and complete the TIGeR-PaC trial. This raises substantial doubt about the company's ability to continue as a going concern.
- Clinical Progress: The Phase III TIGeR-PaC trial enrollment is expected to complete in early 2026, with final data anticipated in 2027. The independent Data Monitoring Committee (DMC) recommended continuing the trial following the second interim analysis in August 2025.
- Commercial Outlook: The company expanded its commercial footprint from 5 to 14 cancer centers in 2025. It hired a Senior Director of Sales and Market Development in August 2025 and plans to add regional sales managers and a marketing director by year-end.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective due to previously identified material weaknesses in internal control over financial reporting (specifically regarding complex transactions, staffing, and segregation of duties). Remediation is ongoing but not yet complete.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status and the 12-month funding gap.
- Revenue Sustainability: Assess the concentration of revenue among the 14 approved centers and the impact of the new sales hires on future growth rates.
- Internal Control Remediation: Monitor progress on fixing the material weaknesses in financial reporting, as this impacts the reliability of future financial statements.
- Clinical Milestones: Track the enrollment progress of the TIGeR-PaC trial and the timing of the final data readout (expected 2027).
- Dilution Risk: Review the outstanding warrant liability ($1.1M) and the large number of potentially dilutive securities (approx. 23.8M shares) that could impact share price upon exercise.